Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
Clinical trial NCT03961698 · UNKNOWN
Trial details
- NCT number
- NCT03961698
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-17
- Primary completion
- 2023-08-31
- Enrollment
- 91
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.